Loading…
The Histone Lysine-specific Demethylase 1 Inhibitor, SP2509 Exerts Cytotoxic Effects against Renal Cancer Cells through Downregulation of Bcl-2 and Mcl-1
Lysine-specific histone demethylase 1 (LSD1), also known as KDM1A, can remove the methyl group from lysine 4 and 9 at histone H3, which regulates transcriptional suppression and activation. Recently, high expression of LSD1 in tumors has been shown to be involved in cancer cell proliferation, metast...
Saved in:
Published in: | Journal of cancer prevention 2020, 25(2), , pp.79-86 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Lysine-specific histone demethylase 1 (LSD1), also known as KDM1A, can remove the
methyl group from lysine 4 and 9 at histone H3, which regulates transcriptional
suppression and activation. Recently, high expression of LSD1 in tumors has been
shown to be involved in cancer cell proliferation, metastasis, and poor
prognosis. We found that SP2509, a potent and reversible inhibitor of LSD1,
induced apoptosis in human renal carcinoma (Caki and ACHN) and glioma (U87MG)
cells. Pharmacological inhibition and siRNA-mediated silencing of LSD1
expression effectively downregulated anti-apoptotic proteins such as Bcl-2 and
Mcl-1. Ectopic expression of these proteins markedly attenuated SP2509-induced
apoptosis. At a mechanistic level, we found that inhibition of LSD1
downregulated Bcl-2 at a transcriptional level. Interestingly, protein
expression of Mcl-1 was modulated at a post-translation level. Our results
reveal that LSD1 could induce apoptotic cell death in renal carcinoma cells
through downregulation of Bcl-2 and Mcl-1. |
---|---|
ISSN: | 2288-3649 2288-3657 |
DOI: | 10.15430/JCP.2020.25.2.79 |